Search
Fenfluramine
go.drugbank.com/drugs/DB00574ApprovedIllicitInvestigationalWithdrawnfrom the market in 1997. … It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression.
Nurulimab
go.drugbank.com/drugs/DB18946InvestigationalNurulimab is under investigation in clinical trial NCT05732805 (A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-pd-1 Compared to Anti-pd-1 Monotherapy as First-line Treatment in
Carglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase. … This rare genetic disorder results in elevated blood levels of ammonia, which can eventually cross the blood–brain barrier and cause neurologic problems, cerebral edema, coma, and death.
Synonyms: N-Carbamylglutamate, N-Carbamyl-L-glutamateDasiglucagon
go.drugbank.com/drugs/DB15226Approved[L39195] In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and older with diabetes. It is available as a subcutaneous injection marketed as ZEGALOGUE. … Although it tends to be more common in type 1 diabetes mellitus, occurring in about 22% to 46% of patients annually, about 7% to 25% of patients with type 2 diabetes mellitus treated with insulin experience
Naloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalIt was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. … Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca.
Categories: Compounds used in a research, industrial, or household settingBardoxolone
go.drugbank.com/drugs/DB12651InvestigationalIn contrast, Bardoxolone in normal cells induces protective antioxidant/anti-inflammatory responses. … Bardoxolone has been used in trials studying the treatment of LYMPHOMA and Solid Tumors.
Pegdinetanib
go.drugbank.com/drugs/DB05931InvestigationalCT-322 is a proprietary Adnectin(TM) protein therapeutic that, in preclinical studies, specifically binds to vascular endothelial growth factor receptor 2 (VEGFR-2), which regulates the primary tumor angiogenesis … As a result, CT-322 blocks all known ligands for VEGFR-2.
Fenpyroximate
go.drugbank.com/drugs/DB16164InvestigationalFenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
Categories: Electron Transport Complex I, antagonists & inhibitorsBesilesomab
go.drugbank.com/drugs/DB13979ApprovedBesilesomab is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis … Utilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the